Monthly dosing of 75
- 作者P. D. Delmas; C. L. Benhamou; Z. Man; W. Tlustochowicz; E. Matzkin; R. Eusebio; J. Zanchetta; W. P. Olszynski; R. R. Recker; M. R. McClung
- 卷第19卷
- 期第7期
- 印刷ISSN0937-941X
- 电子ISSN1433-2965
- 文件大小140.38KB
- 发表时间2008-07
- DOI10.1007/s00198-007-0531-9
- 页码1039-1045
Smoking and fracture risk: a meta-analysisJ. A. Kanis; O. Johnell; A. Oden; H. Johansson; C. De Laet; J. A. Eisman; S. Fujiwara; H. Kroger; E. V. McCloskey; D. Mellstrom; L. J. Melton; H. Pols; J. Reeve; A. Silman; A. Tenenhouse · 2005
Development and use of FRAX® in osteoporosisJ. A. Kanis; E. V. McCloskey; H. Johansson; A. Oden; O. Ström; F. Borgström · 2010
The effects of a FRAX®revision for the USAJ. A. Kanis; H. Johansson; A. Oden; B. Dawson-Hughes; L. J. Melton; E. V. McCloskey · 2010
Interpretation and use of FRAX in clinical practiceJ. A. Kanis; D. Hans; C. Cooper; S. Baim; J. P. Bilezikian; N. Binkley; J. A. Cauley; J. E. Compston; B. Dawson-Hughes; G. El-Hajj Fuleihan; H. Johansson; W. D. Leslie; E. M. Lewiecki; M. Luckey; A. Oden; S. E. Papapoulos; C. Poiana; R. Rizzoli; D. A. Wahl; E. V. McCloskey; Task Force of the FRAX Initiative · 2011
Guidance for the adjustment of FRAX according to the dose of glucocorticoidsJ. A. Kanis; H. Johansson; A. Oden; E. V. McCloskey · 2011
Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronateK. Kayan; H. Johansson; A. Oden; S. Vasireddy; K. Pande; J. Orgee; J. A. Kanis; E. V. McCloskey · 2009
Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UKJ. A. Kanis; E. V. McCloskey; H. Johansson; O. Strom; F. Borgstrom; A. Oden; National Osteoporosis Guideline Group · 2008